Vitaworks IP v. PRINOVA US: Taurine Patent Infringement Resolved After 4+ Years
Vitaworks IP, LLC and Vitaworks, LLC sued PRINOVA US, LLC in Delaware District Court asserting three patents covering taurine synthesis processes applied to QYP-sourced taurine. The case was consolidated with lead docket 19-2259 and ultimately closed on February 5, 2024 via stipulated final judgment — more than four years after filing.
Taurine synthesis IP dispute resolved through consolidation and stipulated judgment
Vitaworks IP, LLC and Vitaworks, LLC filed this infringement action against PRINOVA US, LLC in the Delaware District Court on December 12, 2019, asserting three US patents — US9745258B1, US9815778B1, and US9926265B1 — all directed to taurine chemical synthesis processes. The accused product is QYP-sourced taurine, suggesting the dispute centres on a specific manufacturing origin or process route used by Prinova in its taurine supply chain.
In April 2021, Judge Colm F. Connolly consolidated this case with the companion action 1:19-cv-02259-CFC for all pre-trial purposes, designating 19-2259 as the lead case. A full litigation schedule was set, including a Markman hearing in April 2022 and separate jury trial dates for each docket in March and April 2023 respectively. The case was ultimately closed on February 5, 2024 following a Stipulated Final Judgment entered in the lead case, making this companion docket administratively closed rather than independently adjudicated.
The resolution timeline — over four years from filing — reflects the complexity typical of multi-patent chemical process litigation in Delaware, including claim construction proceedings and extensive fact discovery. The stipulated final judgment in the lead case strongly suggests the parties reached a negotiated resolution, though the specific terms, any licensing arrangement, or monetary outcomes are not disclosed in the available public record. What remains unknown is whether Vitaworks secured an ongoing royalty stream, design-around commitments from Prinova, or a full settlement with a payment.
Filing to Dismissed in 1,516 days
Duration: filed Dec 2019, closed Feb 2024 — over 1,500 days from filing to close
Full party and counsel information
| Role | Nom | Type | Détail |
|---|---|---|---|
| Demandeur | Vitaworks IP, LLC | Entreprise | Taurine IP licensing entity — holder of US9745258B1, US9815778B1, and US9926265B1Search in Eureka ↗ |
| Défendeur | PRINOVA US, LLC | Entreprise | PRINOVA US, LLC — specialty ingredients distributor accused of selling QYP-sourced taurineSearch in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Vitaworks IP, LLCSearch in Eureka ↗ |
| Defendant counsel | Adam Wyatt Poff | Attorney | Counsel for PRINOVA US, LLCSearch in Eureka ↗ |
| Defendant counsel | Alessandra Glorioso | Attorney | Counsel for PRINOVA US, LLCSearch in Eureka ↗ |
| Defendant counsel | Beth Ann Swadley | Attorney | Counsel for PRINOVA US, LLCSearch in Eureka ↗ |
| Defendant counsel | Erin C. Kolter | Attorney | Counsel for PRINOVA US, LLCSearch in Eureka ↗ |
| Defendant counsel | Geoffrey M. Godfrey | Attorney | Counsel for PRINOVA US, LLCSearch in Eureka ↗ |
| Defendant counsel | Paul T. Meiklejohn | Attorney | Counsel for PRINOVA US, LLCSearch in Eureka ↗ |
| Defendant counsel | Robert M. Vrana | Attorney | Counsel for PRINOVA US, LLCSearch in Eureka ↗ |
| Defendant counsel | Ryan B. Meyer | Attorney | Counsel for PRINOVA US, LLCSearch in Eureka ↗ |
| Presiding judge | Judge Jennifer L. Hall | Juge en chef | Delaware District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The scheduling and consolidation order establishes this docket as a companion to lead case 19-2259, with all substantive litigation activity channelled there. The case closed note — ‘CASE CLOSED per Stipulated Final Judgment in LEAD case’ — confirms resolution was reached at the lead docket level, binding this companion action. For Prinova, the stipulated judgment ends litigation exposure on these three patents. For Vitaworks, it secures a court-entered final judgment without the uncertainty of a jury trial, while keeping commercial terms private.
US9745258B1, US9815778B1 & US9926265B1 — Taurine synthesis process patents
The three asserted patents — US9745258B1, US9815778B1, and US9926265B1 — are granted US patents covering taurine manufacturing processes, filed across application numbers US15/268071, US15/366798, and US15/495297. The sequential application numbers filed in 2016–2017 suggest a continuation or divisional prosecution strategy, meaning each patent likely builds on a common specification while claiming distinct process steps or variations. Taurine (2-aminoethanesulfonic acid) is a commercially significant compound manufactured at scale primarily through synthetic chemistry routes.
Vitaworks’ decision to assert all three patents simultaneously against a US distributor of QYP-sourced taurine signals that the portfolio is designed to cover multiple points in the synthesis process — making design-around difficult and invalidation of the entire family expensive. For competitors, ingredient buyers, and distributors active in the taurine supply chain, the combined claim scope of this family represents a meaningful clearance obligation. Any entity sourcing taurine from manufacturers using the implicated process route should treat these patents as active enforcement assets.
Should your taurine supply chain be cleared against US9745258B1 and related patents?
Any company importing, distributing, or formulating with taurine sourced from manufacturers using the QYP process route should consider a freedom-to-operate analysis against this three-patent family. The Vitaworks enforcement action demonstrates these patents are actively asserted against US market participants — not just manufacturers. Energy drink producers, sports nutrition brands, pharmaceutical ingredient buyers, and animal feed compounders all sit within potential exposure range if their taurine supply chain touches the implicated synthesis route.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US9745258B1, US9815778B1, and US9926265B1 against your product specifications and supplier process disclosures in minutes. Claim monitoring alerts will flag any continuation patents or new assertions from Vitaworks IP. For procurement and R&D teams, running this analysis before locking in a taurine supplier is significantly less costly than defending or settling an infringement action of this scale.
Run a freedom-to-operate analysis on US9745258B1 to assess your product’s exposure
Run FTO in Eureka →Similar taurine and amino acid patent infringement cases in US district courts
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the taurine and amino acid IP landscape
Three patents, one distributor defendant, and a confidential resolution — here is what the pattern reveals for ingredient supply chain risk.
Distributors of imported amino acids face direct patent infringement exposure
Vitaworks targeted Prinova as the US distributor rather than the overseas manufacturer. This is a well-established enforcement strategy: US importers and distributors are reachable under 35 U.S.C. § 271(a) even if they did not design or make the accused product. Ingredient companies sourcing taurine or similar amino acids from offshore manufacturers should conduct FTO analysis before distribution, not only at R&D stage.
Multi-patent assertion creates layered litigation risk for process-route suppliers
Asserting three patents covering overlapping aspects of the same synthesis route significantly raises the cost and complexity of defence. Even if one patent is invalidated or designed around, the others may still cover the process. Competitors and ingredient buyers in this space should map claim scope across all three Vitaworks patents — not just the broadest — before assuming a workaround is sufficient.
Vitaworks v PRINOVA — key questions answered
Vitaworks IP asserted three patents: US9745258B1, US9815778B1, and US9926265B1. All three relate to taurine chemical synthesis processes and were filed across application numbers US15/268071, US15/366798, and US15/495297 respectively. The accused product was QYP-sourced taurine sold by PRINOVA US.
Judge Colm F. Connolly consolidated the two cases under FRCP Rule 42(a) in April 2021 because they share common questions of law and fact — both involve the same Vitaworks patent portfolio asserted against taurine-related infringement. Case 19-2259 was designated the lead case, and all future filings were directed there.
The case closed on February 5, 2024 following a Stipulated Final Judgment entered in lead case 1:19-cv-02259. This companion docket was administratively closed as a result. The specific terms of the stipulated judgment — including any financial settlement, licensing terms, or injunctive relief — are not publicly disclosed in the available court record.
QYP-sourced taurine refers to taurine produced via a specific manufacturing process route, likely associated with a particular Chinese producer. Vitaworks’ patents cover taurine synthesis processes, and its infringement theory appears to be that importing and selling taurine manufactured via this route in the US market infringes its process patents — even when the defendant is a distributor rather than the original manufacturer.
Vitaworks IP was represented by Jack B. Blumenfeld of Morris, Nichols, Arsht & Tunnell, LLP — a leading Delaware patent litigation firm. PRINOVA US was represented by a team including Adam Wyatt Poff and Robert M. Vrana of Young, Conaway, Stargatt & Taylor LLP, alongside counsel from Dorsey & Whitney LLP including Paul T. Meiklejohn and Geoffrey M. Godfrey.
PatSnap Eureka searches patents and litigation data to answer instantly.